Back from their travels, Luisa and Kerry “provide an update” after a jam-packed week of East Coast investor meetings. They discuss the obesity pill launches (Wegovy pill versus Foundayo), latest M&A trends (with a focus on Alumis as a potential target on immunology following impressive psoriasis data) and the start of the Q1 reporting season.